17366-48-2

Basic information

• Product Name: Exo-3-hydroxy-8-azabicyclo[3.2.1]octane hydrochloride
• Synonyms: Exo-3-hydroxy-8-azabicyclo[3.2.1]octane hydrochloride;Exo-3-hydroxy-8-azabicycl...;exo-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride;(3-exo)-8-Azabicyclo[3.2.1]octan-3-ol hydrochloride;EXO-3-HYDROXY-8-AZABICYCLO[3.2.1]OCTANE HCL
• CAS NO: 17366-48-2
• Molecular Formula: C₇H₁₃NO*ClH
• Molecular Weight: 163.64516
• Mol File: 17366-48-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: Exo-3-hydroxy-8-azabicyclo[3.2.1]octane hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Exo-3-hydroxy-8-azabicyclo[3.2.1]octane hydrochloride(17366-48-2)
• EPA Substance Registry System: Exo-3-hydroxy-8-azabicyclo[3.2.1]octane hydrochloride(17366-48-2)

Safety Data

• Hazardous Substances Data: 17366-48-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Exo-3-hydroxy-8-azabicyclo[3.2.1]octane hydrochloride is used as a pharmaceutical agent for its potential in treating disorders such as depression, anxiety, and substance abuse. It acts on the central nervous system by modulating the levels of certain neurotransmitters, providing a therapeutic approach to managing these conditions.
Used in Research and Development:
This chemical compound is also used in research and development for the creation of new drugs targeting neurological and psychiatric disorders. Its psychoactive properties and effects on neurotransmitter levels make it a valuable candidate for further exploration and potential applications in the treatment of various mental health conditions.

Upstream product

• 194222-05-4 (1R,3R,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate 
• 185099-67-6 N-Boc-nortropinone 
• 28957-72-4 N-benzylnortropinone 
• 135-97-7 pseudotropine 

Downstream Products

• 1430741-50-6 (1R,3S,5S)-8-(4-iodophenyl)-8-azabicyclo[3.2.1]octan-3-ol 
• 1430741-52-8 (1R,3S,5S)-8-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-8-azabicyclo[3.2.1]octan-3-ol 
• 1032888-16-6 exo-8-[1-(diphenylmethyl)azetidin-3-yl]-8-azabicyclo[3.2.1]octan-3-ol 

Relevant articles and documents

NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to PI3K inhibitors of the formula (I) ? in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.

Phthalazine derivatives and remedies for erectile dysfunction

The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1and R2are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1is a chlorine atom, R2is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.